TLR4 and metabolic dysfunction-associated steatohepatitis: SLBZS treatment inhibited the TLR4/p38 MAPK signaling pathway, attenuating lipid metabolic disturbance, reducing IL-1β, TNF-α, and IL-6 levels, and reversing non-alcoholic steatohepatitis progression [12, 36].